Applied Evidence

How best to address breast pain in nonbreastfeeding women

Author and Disclosure Information

 

References

Bromocriptine, a prolactin inhibitor, has been shown to be more effective than placebo in reducing breast pain, although nausea and dizziness contribute to high discontinuation rates. Bromocriptine is less effective than danazol.40

Goserelin, which is not available in the United States, is a gonadorelin analog (luteinizing hormone-releasing hormone analog) that produces reversible ovarian suppression. One RCT showed that goserelin injection may be more effective than placebo in reducing breast pain.37 Adverse effects include vaginal dryness, hot flashes, decreased libido, oily skin or hair, decreased breast size, and irritability. It is recommended as treatment only for severe refractory mastalgia and that it be used no longer than 6 months.31,37

CASE 1

You reassure Ms. S that her history and physical exam are consistent with cyclic breast pain and not malignancy. You review the current US Preventive Services Task Force recommendations for breast cancer screening in women ages 40 to 49 years (Grade C; women who place a higher value on the potential benefit than the potential harms may choose screening).41 Based on shared decision-making,you offer her a screening mammogram, which returns normal. After confirming that she is using an appropriately-sized supportive bra, you recommend adding 25 g/d of ground flaxseed to her diet.

Women presenting with breast pain should undergo a clinical breast exam in both the upright and supine positions.

After 2 months she reports a 30% improvement in her pain. You then recommend chasteberry extract 4.2 mg/d, which provides additional relief to the point where she can now sleep better and walk for exercise.

CASE 2

You order a diagnostic mammogram of the left breast, which is normal, and an ultrasound that demonstrates a 6-cm deep mass. A biopsy determines that Ms. R has invasive lobular breast cancer—an extremely unlikely outcome of breast pain. She elects to have a double mastectomy and reconstruction and is doing well 4 years later.

CORRESPONDENCE
Sarina Schrager, MD, MS, University of Wisconsin Department of Family Medicine and Community Health, 1100 Delaplaine Ct., Madison, WI, 53715; sbschrag@wisc.edu.

Pages

Recommended Reading

Is it time to taper that opioid? (And how best to do it)
MDedge Family Medicine
Doing our part to dismantle the opioid crisis
MDedge Family Medicine
Moderately high dietary riboflavin linked to fewer migraines
MDedge Family Medicine
Posttraumatic headache may be associated with reduced pain thresholds
MDedge Family Medicine
COPD adds complexity to shared decision making for LDCT lung cancer screening
MDedge Family Medicine
CDC finds that too little naloxone is dispensed
MDedge Family Medicine
Treatment of episodic cluster headache deviates from recommendations
MDedge Family Medicine
USPSTF draft guidance calls for drug use screening
MDedge Family Medicine
MSK Clinic: Evaluating shoulder pain using IPASS
MDedge Family Medicine
CDC, SAMHSA commit $1.8 billion to combat opioid crisis
MDedge Family Medicine